HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: Therefore, we predict the drug response to targeted therapy in high- and low-risk patients, and found that patients with CRC in high-risk were more sensitive to vorinostat (Histone deacetylase (HDAC) inhibitor, was used in Cutaneous T-cell lymphoma) than low-risk patients46.